A genetics team determines that a 59-year-old man referred for multiple colon polyps should also be tested for genes ...

Yatiri used its AI-based proteomics and functional testing platform to identify a biomarker profile for best responders to denfivontinib.

Quotient could receive up to $2.2 billion from the deal, including a $20 million upfront payment plus potential milestones.

The company's lead candidate is an autologous neuron replacement therapy being developed as a treatment for Parkinson's disease.

The appeals panel upheld a portion of appeals raised by Eisai and Eli Lilly over the process NICE used to recommend against ...

The firm has dosed the first patient in a China-based study testing JSKN016 in participants who have failed two or more prior treatments.

The companies have identified an initial set of genetic biomarkers to predict drug response and will validate the findings in ...

Last week, the company got the FDA's tentative approval for the radioligand therapy, but a judge may soon decide whether it's ...

After meeting with the FDA, the company says the agency is aligned with its plan to start a Phase III registrational trial in CLDN 18.2-, PD-L1-positive tumors.

The firm intends to launch the trial based on positive results from an open-label Phase I/IIa trial of sasineprocel, previously known as ANPD001.

The new Andelyn Foundation plans to financially support one patient- or family-founded rare disease charity every year.

Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.